CIK 0001832038 · <br>Emerging growth company
Invivyd, Inc.
Sign in to watch- Ticker
- IVVD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851403134
- Phone
- (781) 819-0080
- Business address
- 205 CHURCH STREET, NEW HAVEN, CT
- Former names
- Adagio Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $177,089
- in 5 filings, $177K under 10b5-1 plans
Net −$177,089. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Andersen Jill −$53K Chief Legal Officer, Secretary sold 19% of stake
- Duke William E. −$32K Chief Financial Officer sold 19% of stake
- Green Julie −$32K Chief Human Resources Officer sold 19% of stake
- Lee Timothy Edward −$32K Chief Commercial Officer sold 19% of stake
- Allen Robert D. III −$29K Chief Scientific Officer sold 17% of stake
Reading 22 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-14 | Andersen Jill Chief Legal Officer, Secretary | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2022-12-14 | Schmidt Peter Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2022-12-14 | Hering David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +700,000 | 700,000 | ||
| 2022-12-14 | Hering David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +900,000 | 900,000 | ||
| 2022-12-06 | Schmidt Peter Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2022-11-03 | Andersen Jill Chief Legal Officer, Secretary | Grant or award · Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2022-10-20 | Lindenboom Christine Director | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-09-01 | Hering David Chief Executive Officer | Purchase | +8,000 | $4.52 | $36K | 8,000 |
| 2022-08-19 | Elia Marc Director | Purchase | +584,451 | $4.62 | $2.7M | 9,248,250 |
| 2022-08-18 | Elia Marc Director | Purchase | +1,265,549 | $4.31 | $5.5M | 8,663,799 |
| 2022-08-17 | Elia Marc Director | Purchase | +1,000,000 | $4.04 | $4.0M | 7,398,250 |
| 2022-07-05 | Hering David Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +2,000,000 | 2,000,000 | ||
| 2022-06-22 | MEANWELL CLIVE Director | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-06-22 | Berry Tamsin Director | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-06-22 | Elia Marc Director | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-06-22 | Mayer Howard Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-06-22 | WYZGA MICHAEL S Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-06-22 | Miller Redonda Director | Grant or award · Stock Option (Right to Buy) | +44,178 | 44,178 | ||
| 2022-06-22 | Heyman Tomas J. Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 | ||
| 2022-06-22 | MCGUIRE TERRANCE Director | Grant or award · Stock Option (Right to Buy) | +75,000 | 75,000 |
Page 8 of 9 · 161 trades